ArticleThe Journal of international medical research2026
Chronic myeloid leukemia in resource-limited settings: Navigating treatment challenges amid limited tyrosine kinase inhibitor access.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesChronic myeloid leukemia presents unique management challenges in resource-limited settings such as Pakistan, where access to advanced molecular monitoring and newer tyrosine kinase inhibitors remains limited. This study evaluates the outcomes in patients with chronic myeloid leukemia in Pakistan, where first-generation tyrosine kinase inhibitors remain the primary mode of treatment due to the lack of newer interventions and insufficient molecular surveillance facilities.MethodsThis retrospective cohort study analyzed 73 patients with chronic myeloid leukemia treated at the Indus Hospital and Health Network, Karachi, Pakistan, between 2018 and 2025. Patients were stratified according to the European Treatment and Outcome Study long-term survival score, and treatment responses were compared using hematologic and molecular remission.ResultsThe proportion of males and females was almost equal. Conventional karyotypes were observed in 92.9% of cases. With imatinib as the first-line therapy, optimal response and treatment failure was observed in 31.3% and 45.3% cases, respectively. A lower complete hematologic response was associated with intermediate-risk scores and atypical fluorescence in situ hybridization results. The intent to change therapy was found to be a powerful predictor of better overall response (adjusted odds ratio: 23.620,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.